-
Recent Posts
Recent Comments
Archives
- October 2012
- December 2011
- November 2011
- September 2011
- March 2011
- December 2010
- November 2010
- September 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- November 2009
- October 2009
- September 2009
- July 2009
- June 2009
- February 2009
- January 2009
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- February 2007
- December 2006
- November 2006
- October 2006
- August 2006
- April 2006
- March 2006
- December 2005
- November 2005
- July 2005
- March 2005
- February 2005
- January 2005
- December 2004
- November 2004
- October 2004
- September 2004
- August 2004
Categories
Meta
Category Archives: Interactions
Aliskiren (Rasilez®) and serious adverse drug reactions
Novartis has prematurely halted the AlTITUDE study following an interim safety review. ALTITUDE was a trial of the direct renin inhibitor aliskiren (Rasilez®) in type 2 diabetes and renal impairment patients, with a high risk of cardiovascular and renal events, … Continue reading
Posted in ADRs, Interactions
Comments Off
Clopidogrel and PPIs: reduced efficacy?
Interesting news from the FDA: The FDA is aware of published reports that clopidogrel (marketed as Plavix) is less effective in some patients than it is in others. Differences in effectiveness may be due to genetic differences in the way … Continue reading
Posted in FDA, Interactions
Comments Off
Interaction between atazanavir/ritonavir and omeprazole
The EMEA report new pharmacokinetic data showing that atazanavir when combined with ritonavir has an interaction with omeprazole 40mg resulting in a 76% reduction in atazanavir AUC and 78% reduction in Cmin. EMEA public statement
Posted in EMEA, Interactions
Comments Off